Leading scientists and researchers and business people to support them
Board of Directors
Dr Bellur Prabhakar
Chief Scientific Officer and Co-founder
Dr. Prabhakar obtained his BSc degree in biology and chemistry, and MSc degree in medical microbiology from the University of Mysore, India. He came to the United States in 1974 to pursue higher studies. He obtained his PhD degree from the highly prestigious Johns Hopkins University in Baltimore. Subsequently, he did a two year post-doctoral fellowship at University of Pennsylvania, a prestigious Ivy-league school. After completing his post-doctoral fellowship, Dr. Prabhakar joined the National Institutes of Health (NIH) in Bethesda, Maryland as a staff fellow and rose through the ranks very quickly to become a tenured senior investigator; a recognition bestowed on less than 5% of the staff fellows at NIH. Dr. Prabhakar joined the University of Texas Medical Center in Galveston as a tenured professor. In 1997, he was recruited as the head of the department of Microbiology and Immunology in the college of medicine at the University of Illinois, Chicago (UIC).
A very distinguished scientist, Dr. Prabhakar has been funded by the NIH continuously for the past twenty years. He has nearly 200 publications to his credit in journals including Science, Nature, New England Journal of Medicine, PNAS, and the Journal of Clinical Investigation. He holds several patents on technologies that can be harnessed to develop treatments for cancer, autoimmune diseases and virus infections.
At UIC, Dr. Prabhakar has held the following leadership positions: 1997-present
Professor and Head, Department of Microbiology and Immunology; 2004-present Director, Immunology Center, College of Medicine; 2009-2011, Associate Director, Novel Translational & Collaborative Studies, CCTS; 2013-Associate Dean for Research, College of Medicine.
He has an excellent track record of pursuing innovative science of very high clinical relevance and providing outstanding scientific leadership.
Chief Executive Officer
Sidney Hopps has over 18 years experience in international financial markets in equity and equity derivatives securitization and sales in New York, Chicago, London, and Paris.
Prior to joining Jivana Biotechnology, Mr. Hopps spent many years working with biotechnology companies in the public markets while at UBS and First Albany Corp.
Most recently, Mr Hopps was a partner in Global Diversified Fund Management.
Mr Hopps is responsible for developing the firm's legal and regulatory pathways, capital raising, drug delivery technology alliances, and managing pre clinical trials.
Mr Hopps is a member of 700 for Science, a collaborative community dedicated to bringing early stage biotechnologies to life.
Kenneth J Templin, CMA
Chief Financial Officer
Ken Templin is a retired Business Resource Manager from Caterpillar where he spent almost 37 years working in both the engine and machinery businesses in multiple locations throughout the world.
More recently, he is consulting small and growing businesses in a variety of business segments.
Ken’s Caterpillar career included various ﬁnancial staﬀ, supervisory and manager positions supporting both plant operations and corporate oﬃces.
His accomplishments included deploying 6 Sigma as a lead champion for one of Cat’s business units, acquiring businesses and forming new strategic businesses, working on a special team to develop enterprise wide realignment issues for Cat’s Execuive Oﬃce, guiding the installaion of a multi-‐plant Enterprise Resource Planning system and leading the development of a global ﬁnance transformation strategy that is enabling the way to global common processes supported by a single integrated system.
Rich Schuler is retired from the financial service industry. During his time he started and ran the Schuler Execution Group a broker trader at the CBOT. As an Associate Member Mr Schuler and his group handled trade execution for banks, hedge funds and CTA. Mr Schuler was also the head trader for the Asian trading session for CTA Trout Trading Company for a number of years before they moved their operations to Bermuda.
Since leaving the CBOT Mr Schuler has been investing in a number of startup ventures including Getco, Jivana, PharmaCann and Intouch Holdings.
Mr. Schuler is an investor in Jivana and also is involved with capital raising and strategic planning for Jivana.
Mr. Sage, a registered patent attorney since 1993 and founder of Kalamazoo, Mich.-based Hueschen & Sage, PLLC, specializes in advising innovator pharmaceutical, dermatological and fine chemical companies in portfolio development, prosecution, management, agency registration, enforcement and partnering.
Mr. Sage graduated from Kalamazoo College with a BA in Biology in 1986, and from Loyola University in Chicago with a JD in 1992.
He started his career as a biochemist with The Upjohn Company, conducting pharmacological research on putative Alzheimer’s compounds.